We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Genedrive Plc | LSE:GDR | London | Ordinary Share | GB00B1VKB244 | ORD 1.5P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-0.25 | -4.26% | 5.625 | 5.25 | 6.00 | 6.00 | 5.50 | 5.88 | 744,959 | 16:18:25 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Coml Physical, Biologcl Resh | 55k | -5.15M | -0.0447 | -1.26 | 6.47M |
Date | Subject | Author | Discuss |
---|---|---|---|
19/6/2021 14:43 | I think the CEO is waiting for the release of the POC Test before announcing sales. You can bet BC and Genedrive have sold a lot of tests and the S.P will head north. More patience required, POC due anytime now. | blackvulture | |
19/6/2021 12:16 | After great initial promise, this company appears to be going to the dogs. I don't understand it. | petersinthemarket | |
18/6/2021 10:33 | A few buys rattling thro' in last few minutes | mortimer7 | |
18/6/2021 09:09 | Sells of 5,10,20, and 30.000 throughout the day for last few weeks .share they institutions offloading.will it better for pi to get rid of them . | capitol2 | |
17/6/2021 15:52 | Methods and analysis The genedrive POCT can detect the m.1555A>G variant in 26?min from buccal swab. This system will be integrated into the clinical pathways at two large UK neonatal centres over a minimum 6-month period. The primary outcome is the number of neonates successfully tested for the variant out of all babies prescribed antibiotics. As a secondary outcome, clinical timings will be compared with data collected prior to implementation, measuring the impact on routine practice. | blackvulture | |
17/6/2021 15:28 | Decent news on twitter. | loafofbread | |
17/6/2021 12:46 | Man this dog drips down every day ... Nightmare !! | pal44 | |
17/6/2021 11:16 | Some of news needed.more selling today .buys still appear. | capitol2 | |
17/6/2021 09:52 | Good luck butcI am getting wary of GDR - no Directors share purchase, no FDA, no sales etc. We live in hope | maxplus2 | |
16/6/2021 10:11 | Sales rns due. If rns released today .or any day how high share go. | capitol2 | |
16/6/2021 10:11 | Sales rns due. If rns released today .or any day how high share go. | capitol2 | |
16/6/2021 10:08 | P O C. Rns. due | capitol2 | |
16/6/2021 10:07 | AIHL. Rns due . | capitol2 | |
16/6/2021 09:36 | haha mad hares running around today ! i dont think the GDR BOD have us PI's interest at heart .DB is on £400+ and oversees the share price drip every day now you would be thinking them lot are working their socks off for us !!! | pal44 | |
16/6/2021 09:09 | Level 4 buy order hit.. taken a few at 58p as predicted.. my nob is visible on the table, it's the obvious one. Hope this is helping Sanks..playing the market like a PlayStation game | sanks | |
16/6/2021 08:38 | Not a bean .are they releasing rns soon. | capitol2 | |
16/6/2021 08:38 | Not a bean .are they releasing rns soon. | capitol2 | |
15/6/2021 21:50 | Have these tested anyone with COVID yet? ?? | g2theary | |
15/6/2021 21:36 | Man this share is a nightmare! | pal44 | |
15/6/2021 15:15 | The cheap Covid-19 test kits from China are killing off the competition including that of GDR. The Covid-19 business has been totally waste of time and money for GDR - no FDA approval, no sales etc. Looks like GDR have to rely on other portfolio such as AIHL.Worse still that none of the Directors of GDR have purchased shares in the company | maxplus2 | |
14/6/2021 13:01 | Yea buy quote dipped.not let buy bean .are they releasing rns soon | capitol2 | |
14/6/2021 12:26 | buy quote moved down me thinks | mrshaungcm |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions